LIXT Lixte Biotechnology, Inc. Earnings per share for the last twelve months

LIXT (Lixte Biotechnology Holdings Inc.) - company brandmark

Lixte Biotechnology (LIXT) is targeting expansion by scaling its LB-100 platform to enhance chemotherapy. The fundamental TTM net income per share metric visualizes these ambitions, with this figure equaling -1.12. A current R&D plateau and a lack of sales are constraining financial growth, while drug delivery to medical centers relies on strict pharmaceutical transportation standards.

LIXT (Lixte Biotechnology) Net earnings per share for the last 12 months history from 07/04/2022 to 07/06/2026

Lixte Biotechnology Holdings Inc. - analytical breakdowns and key metrics (LIXT)

- current quotes and average value forecast:
Price Chart Lixte Biotechnology|LIXT - Average Forecast Price
- market capitalization data:
Market Value Lixte Biotechnology Holdings, Inc.|LIXT - Business Value
- shareholders' equity book value data:
Book Value per Share Lixte Biotechnology|LIXT - Company Net Assets|Market Value to Book Value Ratio lixte.com|LIXT - Company Assets
- debt burden and liquidity indicators:
Debt to Equity Lixte Biotechnology|LIXT - Long-Term Debt to Equity|Short-Term Debt to Equity Lixte Biotechnology Holdings|LIXT - Company Cumulative Debt|Debts to Book Capitalization Lixte Biotechnology Holdings, Inc.|LIXT - Long-Term Indebtedness|Company Current Liabilities Lixte Biotechnology|Quick Liquidity Indicator lixte.com
- net income and valuation multiples indicators:
LIXT - Final Profit|Future Profit Lixte Biotechnology|LIXT - Market Price to Net Income Ratio|Forward P/E Multiple Lixte Biotechnology Holdings, Inc.|LIXT - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Lixte Biotechnology Holdings, Inc.|LIXT - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Lixte Biotechnology|LIXT - Earnings per share for the trailing year|Quarterly EPS earnings growth lixte.com|LIXT - Earnings growth in current year|Net earnings per share growth forecast for next year Lixte Biotechnology
Basic company analysis:Lixte Biotechnology (LIXT)
Mass-produced product of Lixte Biotechnology Holdings

Lixte Biotechnology focuses on developing highly specialized protein phosphatase inhibitors for chemotherapy. A heavy reliance on a single molecule makes earnings per share a key indicator of financial stability. This metric divides total net income by the number of shares, eliminating the impact of issuance manipulations. This allows for an assessment of the investor's actual equity income. Analyzing the 12-month net income per share chart helps in rebalancing the portfolio in a timely manner.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months hutch-med.com|Nuvation Bio (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (Monopar Pharma) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Inhibrx Corp (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics, Inc. HRTX|Nuvectis Pharma Inc. - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals, Inc.|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year beyondspringpharma.com BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Citius Pharma CTXR|Net earnings per share for the last 12 months CLRB (Cellectar)|BLRX (BioLineRx Corporation) - Earnings per share for the trailing year|Can-Fite BioPharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea Therapeutics Inc.)|Kazia - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (Silexion Therapeutics Corp)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Chimerix Inc (CMRX)|Earnings per share for the last twelve months Cyclacel Pharmaceuticals|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Therapeutics Inc (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech Corp) - Earnings per one share for the last 12 months